Professor Sharona Hoffman, Co-Director of the Law-Medicine Center, recently published an article entitled “Specialty Drugs and the Health Care Cost Crisis,” co-authored with Professor Isaac Buck.
The paper focuses on specialty drugs, which are generally high-cost drugs that require special handling and are used to treat complex conditions such as cancer or multiple sclerosis. The article argues that specialty drugs raise significant legal and ethical questions that merit attention from the public and policymakers. These relate to the way drugs are designated as specialty drugs, their cost, conflicts of interest, patient choice constraints, and potential antitrust problems.
Hoffman also published an op-ed on the topic in The Conversation.